Accepted for Publication: July 26, 2022.
Published Online: September 15, 2022. doi:10.1001/jamaoncol.2022.4175
Corresponding Author: Aleix Prat, MD, PhD, Hospital Clinic of Barcelona, Villarroel 170, Escalera 2, Planta 5, 08036 Barcelona, Spain (alprat@clinic.cat).
Conflict of Interest Disclosures: Dr Prat reported grants and personal fees from Daiichi Sankyo, AstraZeneca, and Pfizer during the conduct of the study; and personal fees from Amgen, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Nanostring Technologies, Novartis, Oncolytics Biotech, Puma Biotechnology, and Roche outside the submitted work. In additional, Dr Prat is a cofounder and stock owner of Reveal Genomics and reports 2 patents licensed to Reveal Genomics (HER2DX and WO 2018/103834). Dr Bardia reported grants and consulting fees from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Sankyo/AstraZeneca, Eli Lilly, and Foundation Medicine during the conduct of the study. Dr Curigliano reported advisory board membership and personal fees from AstraZeneca, Daiichi Sankyo, Bristol Myers Squibb, Roche, and Seagen; speaking fees from Novartis, Eli Lilly, Pfizer, and Gilead; and grants from Foundation One and Merck, all outside the submitted work. Dr Hammond reported personal fees from Daiichi Sankyo during the conduct of the study. Dr Loibl reported advisory board membership fees and/or funded research paid to the institute by Seagen, AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, EirGenix, GlaxoSmithKline, Gilead, Eli Lilly, Merck, Molecular Health, Novartis, Pfizer, Pierre Fabre, Relay Therapeutics, Roche, Sanofi, and Seagen, all outside the submitted work. In addition, Dr Loibl reported patents for EP14153692.0 (pending immunsignature in TNBC), EP21152186.9 (pending signature for CDK 4/6 inhibitor), EP15702464.7 (issued predicting response to an anti-ERBB2 containing therapy), EP19808852.8 (pending), and Digital Ki67 Evaluator (royalties paid from VM Scope GmbH to institute). Dr Tolaney reported grants and honoraria from AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Gilead, Exelixis, Bristol Myers Squibb, Eisai, Nanostring, Puma Biotechnology, Cyclacel, Sanofi, Odonate, Seagen, and Daiichi Sankyo; and personal fees from Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepis, CytomX, Certara, Mersana Therapeutics, Ellipses Pharma, 4D Pharma, OncoSec Medical, Chugai Pharmaceuticals, BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, and ZetaGen, all outside the submitted work. Dr Viale reported consulting fees from AstraZeneca and Agilent; advisory board fees from Daiichi Sankyo, Roche, and Merck Sharp & Dohme Oncology during the conduct of the study; and grants from AstraZeneca, all outside the submitted work.
Funding/Support: Financial support for the writing of the manuscript was provided by AstraZeneca, which in March 2019 entered into a global development and commercialization collaboration agreement with Daiichi Sankyo for trastuzumab deruxtecan (DS-8201).
Additional Contributions: Medical writing support was provided by Jackie Highland, PhD (Articulatescience) and funded by AstraZeneca in accordance with Good Publication Practice guidelines. The manuscript was reviewed for medical accuracy by AstraZeneca and Daiichi Sankyo; however, the authors retained full control of the content and made the final decisions for all aspects of this article.
6.Wolff
AC , Hammond
MEH , Allison
KH ,
et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update.
J Clin Oncol. 2018;36(20):2105-2122. doi:
10.1200/JCO.2018.77.8738
PubMedGoogle ScholarCrossref 7.Denkert
C , Seither
F , Schneeweiss
A ,
et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol. 2021;22(8):1151-1161. doi:
10.1016/S1470-2045(21)00301-6
PubMedGoogle ScholarCrossref 12.Exman
P , Tolaney
SM . HER2-positive metastatic breast cancer: a comprehensive review.
Clin Adv Hematol Oncol. 2021;19(1):40-50.
PubMedGoogle Scholar 21.Bao
KKH , Sutanto
L , Tse
SSW , Man Cheung
K , Chan
JCH . The association of ERBB2-low expression with the efficacy of cyclin-dependent kinase 4/6 inhibitor in hormone receptor-positive, ERBB2-negative metastatic breast cancer.
JAMA Netw Open. 2021;4(11):e2133132. doi:
10.1001/jamanetworkopen.2021.33132
PubMedGoogle ScholarCrossref 26.Roßwag
S , Cotarelo
CL , Pantel
K ,
et al. Functional characterization of circulating tumor cells (CTCs) from metastatic ER+/HER2- breast cancer reveals dependence on HER2 and FOXM1 for endocrine therapy resistance and tumor cell survival: implications for treatment of ER+/HER2- breast cancer.
Cancers (Basel). 2021;13(8):1810. doi:
10.3390/cancers13081810
PubMedGoogle ScholarCrossref 29.Modi
S , Park
H , Murthy
RK ,
et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study.
J Clin Oncol. 2020;38(17):1887-1896. doi:
10.1200/JCO.19.02318
PubMedGoogle ScholarCrossref 30.Banerji
U , van Herpen
CML , Saura
C ,
et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol. 2019;20(8):1124-1135. doi:
10.1016/S1470-2045(19)30328-6
PubMedGoogle ScholarCrossref 31.Wang
J , Liu
Y , Zhang
Q ,
et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies.
J Clin Oncol. 2021;39(suppl 15):1022. doi:
10.1200/JCO.2021.39.15_suppl.1022Google ScholarCrossref 32.Clifton
GT , Hale
D , Vreeland
TJ ,
et al. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer.
Clin Cancer Res. 2020;26(11):2515-2523. doi:
10.1158/1078-0432.CCR-19-2741
PubMedGoogle ScholarCrossref 34.Fehrenbacher
L , Cecchini
RS , Geyer
CE
Jr ,
et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2.
J Clin Oncol. 2020;38(5):444-453. doi:
10.1200/JCO.19.01455
PubMedGoogle ScholarCrossref 35.Gianni
L , Lladó
A , Bianchi
G ,
et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
J Clin Oncol. 2010;28(7):1131-1137. doi:
10.1200/JCO.2009.24.1661
PubMedGoogle ScholarCrossref 36.Burris
HA
III , Rugo
HS , Vukelja
SJ ,
et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
J Clin Oncol. 2011;29(4):398-405. doi:
10.1200/JCO.2010.29.5865
PubMedGoogle ScholarCrossref 37.Krop
IE , LoRusso
P , Miller
KD ,
et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
J Clin Oncol. 2012;30(26):3234-3241. doi:
10.1200/JCO.2011.40.5902
PubMedGoogle ScholarCrossref 38.Modi
S , Jacot
W , Yamashita
T ,
et al; DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
N Engl J Med. 2022;387(1):9-20. Published online June 5, 2022. doi:
10.1056/NEJMoa2203690
PubMedGoogle ScholarCrossref 39.Hamilton
E , Shapiro
CL , Petrylak
D ,
et al. Trastuzumab deruxtecan with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study.
Cancer Res. 2021;81(4)(suppl):PD3-PD07. doi:
10.1158/1538-7445.SABCS20-PD3-07Google ScholarCrossref 40.Schmid
P , Im
SA , Armstrong
A ,
et al. BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—initial results from arm 1, d+ paclitaxel (P), and arm 6, d+ trastuzumab deruxtecan (T-DXd).
J Clin Oncol. 2021;39(suppl 15):1023. doi:
10.1200/JCO.2021.39.15_suppl.1023Google ScholarCrossref 41.Cardoso
F , Dirix
L , Conte
P ,
et al. Phase II study of single agent trifunctional antibody ertumaxomab (anti-HER-2 & anti-CD3) in HER-2 low expressing hormone-refractory advanced breast cancer patients (ABC).
Cancer Res. 2010;70(24_Supplement):P3-14-21. doi:
10.1158/0008-5472.SABCS10-P3-14-21Google ScholarCrossref 42.Pistilli
B , Wildiers
H , Hamilton
EP ,
et al. Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
J Clin Oncol. 2020;38(suppl 15):1037. doi:
10.1200/JCO.2020.38.15_suppl.1037Google ScholarCrossref 43.Nordstrom
JL , Gorlatov
S , Zhang
W ,
et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Breast Cancer Res. 2011;13(6):R123. doi:
10.1186/bcr3069
PubMedGoogle ScholarCrossref 45.Swain
SM , Nishino
M , Lancaster
LH ,
et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)−related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management.
Cancer Treat Rev. 2022;106:102378. doi:
10.1016/j.ctrv.2022.102378
PubMedGoogle ScholarCrossref 49.Ogitani
Y , Aida
T , Hagihara
K ,
et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1.
Clin Cancer Res. 2016;22(20):5097-5108. doi:
10.1158/1078-0432.CCR-15-2822PubMedGoogle ScholarCrossref 52.Skidmore
L , Sakamuri
S , Knudsen
NA ,
et al. ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers.
Mol Cancer Ther. 2020;19(9):1833-1843. doi:
10.1158/1535-7163.MCT-19-1004
PubMedGoogle ScholarCrossref 59.Gupta
S , Zhang
J , Jerusalem
G . The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective.
Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):929-940. doi:
10.1586/14737167.2014.949243
PubMedGoogle ScholarCrossref 60.Li
CH , Karantza
V , Aktan
G , Lala
M . Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Breast Cancer Res. 2019;21(1):143. doi:
10.1186/s13058-019-1210-4
PubMedGoogle ScholarCrossref 63.Sharifi
MN , Anandan
A , Grogan
P , O’Regan
RM . Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Cancer. 2020;126(15):3400-3416. doi:
10.1002/cncr.32931
PubMedGoogle ScholarCrossref 64.Hugo
HS , Bardia
A , Marmé
F ,
et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
J Clin Oncol. 2022;40(suppl 17).
Google Scholar 65.Giuliano
M , Trivedi
MV , Schiff
R . Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications.
Breast Care (Basel). 2013;8(4):256-262. doi:
10.1159/000354253
PubMedGoogle ScholarCrossref 69.Gustavson
M , Haneder
S , Spitzmueller
A ,
et al. Novel approach to HER2 quantification: digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients. Poster presented at 2020 San Antonio Breast Cancer Symposia; December 8-11, 2020. Accessed August 15, 2022.
https://aacrjournals.org/cancerres/issue/81/4_Supplement 72.Lambein
K , Van Bockstal
M , Vandemaele
L ,
et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.
Am J Clin Pathol. 2013;140(4):561-566. doi:
10.1309/AJCP4A7KTAYHZSOE
PubMedGoogle ScholarCrossref 73.Baehner
FL , Achacoso
N , Maddala
T ,
et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
J Clin Oncol. 2010;28(28):4300-4306. doi:
10.1200/JCO.2009.24.8211
PubMedGoogle ScholarCrossref 74.Viale
G , Slaets
L , Bogaerts
J ,
et al; TRANSBIG Consortium & the MINDACT Investigators. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.
Ann Oncol. 2014;25(4):816-823. doi:
10.1093/annonc/mdu026
PubMedGoogle ScholarCrossref 75.Prat
A , Guarneri
V , Pascual
T ,
et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
EBioMedicine. 2022;75:103801. doi:
10.1016/j.ebiom.2021.103801
PubMedGoogle ScholarCrossref 77.Do
M , Kim
H , Yeo
I ,
et al. Clinical application of multiple reaction monitoring-mass spectrometry to human epidermal growth factor receptor 2 measurements as a potential diagnostic tool for breast cancer therapy.
Clin Chem. 2020;66(10):1339-1348. doi:
10.1093/clinchem/hvaa178
PubMedGoogle ScholarCrossref 79.Jakobsen
MR , Teerapakpinyo
C , Shuangshoti
S , Keelawat
S . Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer.
Pathol Res Pract. 2018;214(12):2087-2092. doi:
10.1016/j.prp.2018.10.015
PubMedGoogle ScholarCrossref 80.Vandenberghe
ME , Scott
ML , Scorer
PW , Söderberg
M , Balcerzak
D , Barker
C . Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer.
Sci Rep. 2017;7:45938. doi:
10.1038/srep45938
PubMedGoogle ScholarCrossref